SCS Capital Management LLC bought a new position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 81,452 shares of the company's stock, valued at approximately $137,000.
Other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Sana Biotechnology by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company's stock worth $457,000 after buying an additional 6,613 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Sana Biotechnology by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company's stock worth $578,000 after buying an additional 7,230 shares in the last quarter. Hsbc Holdings PLC increased its stake in Sana Biotechnology by 26.5% in the 1st quarter. Hsbc Holdings PLC now owns 41,377 shares of the company's stock worth $65,000 after buying an additional 8,673 shares in the last quarter. Rhumbline Advisers increased its stake in Sana Biotechnology by 5.4% in the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company's stock worth $306,000 after buying an additional 9,359 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in Sana Biotechnology by 25.4% in the 4th quarter. ProShare Advisors LLC now owns 47,808 shares of the company's stock worth $78,000 after buying an additional 9,679 shares in the last quarter. 88.23% of the stock is owned by institutional investors.
Sana Biotechnology Stock Performance
NASDAQ SANA traded up $0.27 during trading on Thursday, hitting $3.31. The stock had a trading volume of 2,203,119 shares, compared to its average volume of 5,709,794. The stock has a market capitalization of $785.96 million, a price-to-earnings ratio of -3.12 and a beta of 1.88. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $7.30. The stock has a 50 day simple moving average of $3.69 and a 200 day simple moving average of $2.72.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. On average, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have recently weighed in on SANA shares. Morgan Stanley started coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price objective for the company. JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $8.00.
Read Our Latest Stock Report on Sana Biotechnology
Sana Biotechnology Company Profile
(
Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Articles
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
